News & Events

Learn about what's new with CMC Biologics

AGC Biologics Expands Capacity at Copenhagen, Denmark Facility

News

Strategic expansion will meet increasing global demand for biopharmaceutical development and manufacturing 

COPENHAGEN, Denmark and BOTHELL, Wash., 
Aug. 22, 2018
 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that as part of its global expansion strategy, the company is increasing manufacturing capacity at its Copenhagen, Denmark facility. 

BioProcess International (BPI East) 2018, Sept 4-7, Boston, MA

Events

Headed to BPI East in Boston, MA?
Make sure to stop by AGC Biologics Booth #615!

AGC Biologics Inaugurates New Global Headquarters Facility in Bothell, WA

News

Ribbon Cutting Ceremony Held to Commemorate Company Milestone 

BOTHELL, Wash., – July 24, 2018 – AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, celebrated the opening of the company’s new Global Headquarters facility in Bothell, Washington on Wednesday, July 18, 2018.

AGC Biologics to Participate in Boston’s BIO International Convention

News

 

BOTHELL, Wash. – May 30, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will participate in the upcoming BIO International Convention in Boston, Mass. on June 4-7, 2018.

AGC Biologics Cleared for Commercial Manufacture of Portola's FDA-Approved Andexxa®

News

Drug Substance produced in AGC Biologics' facility in Bothell, Washington 

BOTHELL, Wash. – May 24, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that it will supply bulk drug substance for the launch of Portola Pharmaceuticals' Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

AGC Biologics enters into Commercial Supply Agreement with MacroGenics

News

BOTHELL, Wash. -- May 10, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that in late 2017 it entered into a commercial supply agreement with MacroGenics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, for the manufacture of margetuximab, a clinical-stage, novel immune-optimized monoclonal antibody.

AGC Biologics enters into Commercial Manufacturing Agreement with Horizon Pharma plc

News

Manufacture of teprotumumab for treatment of thyroid eye disease
 

COPENHAGEN, DK -- May 3, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today it has entered into an agreement with Horizon Pharma plc for commercial supply of teprotumumab, a monoclonal antibody biologic for the treatment of moderate-to-severe active thyroid eye disease (TED).

BIO International Convention 2018, June 4-7, Boston, MA

Events

We're looking forward to this year's BIO International Convention in Boston, MA! Don't miss the AGC Biologics booth #663.

OutsourcedPharma East, May 14-15, Boston, MA

Events

Will you be in Boston this May for the OutsourcedPharma East Conference? Be sure to stop by Booth #123!

BIO Korea 2018, May 9-11, COEX, Seoul, South Korea

Events

Join us at the 2018 BIO Korea International Conference!
We'll be at Booth e48.  Let's talk about AGC Biologics' expanded capabilities across the globe, and how we can collaborate on your next challenge.

Follow Us
Join us on LinkedIn Follow us on Twitter